Hospital-level care for acutely ill adults in the comfort of their own home.
Learn more
Hospital-level care for acutely ill adults in the comfort of their own home. Learn more

When you see each
patient a million
times a day...

...You see the
bigger picture.

Every second, our FDA-cleared AI-based ecosystem compares 20+ physiological signals* from a wearable biosensor with data from millions of other chronic patients. The result? Powerful pattern recognition designed to help clinicians predict and prevent deterioration before it happens.

When you see each patient a million times a day... You see the bigger picture.

Every second, our FDA-cleared AI-based ecosystem compares 20+ physiological signals* from a wearable biosensor with data from millions of other chronic patients. The result? Powerful pattern recognition that helps predict and prevent deterioration before it happens.

We're powering personally predictive care...
so everyone can see better outcomes.

What if patients suffering from heart failure, COPD, chronic pain, or cancer could spend less time in hospitals and more time feeling confident and cared for at home? What if networks, clinicians, and payers could turn fewer readmissions into a higher level of care for all? And what if drug companies could more dramatically demonstrate, in real-time, the physiological impact and value of pharmacotherapy candidates?

At Biofourmis, we use patient physiology data and advanced analytics to turn those "what-ifs" into "ah-has" for some of the world's most respected healthcare providers and pharmaceutical companies—collaborators like Novartis, Chugai, Brigham and Women's Hospital, and Mayo Clinic that use our clinically validated, predictive platform to more precisely manage, intervene, and treat chronic patients in a way that's proactive and liberating. That's the power of personally predictive care.

Get To Know Us

The Biovitals® platform shows you more than patient data.
It can help show you patient futures.

Our Biovitals® platform collects and interprets vast amounts of population metadata and compares it to real-time patient physiological signals to provide a clearer picture of chronic patients and their disease trajectory—a real-time picture designed to help clinicians predict and prevent serious medical events. Its actionable insights powered by machine learning, deep neural networks, and a clinical-grade Everion® wearable.

See How Biovitals® Works

Predict and prevent costly medical events with a modular, user-friendly platform.

Biovitals® delivers actionable information by bringing disease, data, machine-learning, and clinical-grade hardware together in one customizable ecosystem. Learn how we can tailor Biovitals® to improve real-world outcomes for the unique needs of health systems, payers and pharmaceutical companies.

Hospitals Icon Created with Sketch.
Payors Icon Created with Sketch.
Pharma Icon Created with Sketch.

Health Systems

  • Improve clinical outcomes by reducing readmissions and ED visits
  • Improve workflow efficiencies, care team capacity and ongoing communication with patients
  • Realize more rapid personalized treatment and communication for efficient management of patients with complex chronic conditions

Payers

  • Reduce overall healthcare expenditures while improving clinical outcomes
  • Improve quality of life for members with complex chronic conditions
  • Deliver members more targeted and timely intervention and engagement support based on their personalized needs

Pharmaceutical Companies

  • Augment drug efficacy and outcomes using drug + digital intervention
  • Accelerate development time frames by accelerating clinical trials using digital tools
  • Increase patient share, adherence, and engagement
  • Increase reimbursements and/or value-based payments
Hospitals Icon Created with Sketch.

Health Systems

Payors Icon Created with Sketch.

Payers

Pharma Icon Created with Sketch.

Pharmaceutical Companies

Clinical evidence and science guides everything we do

Around the world and across multiple collaborations and studies, our Biovitals® Platform is helping clinical teams see patients like never before.

Collaborators and Investors

We're proud to collaborate with some of the world's most respected healthcare organizations, research hospitals, and biopharma companies. Together, we're improving patient outcomes, advancing clinical research, reducing healthcare costs, and accelerating drug research and development.

COLLABORATORS

INVESTORS

Biofourmis in the news.

Let's get you up to speed.

Press Release
Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion

BOSTON, Sept. 3, 2020 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2,[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.

September 3, 2020

The Post-Covid World: 16 Ways Telehealth Could Transform Healthcare

Unnecessary patient hospital stays are not only a drain on hospitals’ resources, but also a risk for other patients.

Telehealth can reduce unnecessary patient stays by transferring non-acute patients to their homes, where they can continue receiving appropriate care.

For instance, Biofourmis‘ AI-based remote patient monitoring technology allows stabilized cardiac patients to continue to be cared for at home. Its wearable armband monitors patient vitals 24/7, detects cardiac abnormalities, and alerts clinicians on potential intervention measures.

August 24, 2020

PR Newswire
Biofourmis’ AI-Powered Remote Monitoring Platform Deployed to Monitor COVID-19 Patients in Singapore

BOSTON, [U.S.] AND SINGAPORE, July 29 and 30, 2020 – Biofourmis, a global leader in digital therapeutics that powers personalized predictive care, announced today that its Biovitals® Sentinel platform has been deployed by the Ministry of Health (MOH) in Singapore to remotely monitor COVID-19-positive patients to aid in early detection of deterioration and to enable clinicians and nurse teams to intervene early.

July 29, 2020

PR Newswire
Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

TOKYO and BOSTON, July 21, 2020 /PRNewswire/ -- and July 22, 2020 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis.

July 21, 2020

Biofourmis News

Let's connect.

We're helping some of the most respected names in healthcare deliver measurably better outcomes. Let us show you what personally predictive care can do for your organization.

Contact Us